Q2 EPS Estimate for Corcept Therapeutics Reduced by Analyst

Corcept Therapeutics Incorporated (NASDAQ:CORT - Free Report) - Equities researchers at HC Wainwright cut their Q2 2025 EPS estimates for shares of Corcept Therapeutics in a research note issued to investors on Tuesday, May 6th. HC Wainwright analyst S. Ramakanth now forecasts that the biotechnology company will earn $0.08 per share for the quarter, down from their prior forecast of $0.47. HC Wainwright currently has a "Buy" rating and a $145.00 price target on the stock. The consensus estimate for Corcept Therapeutics' current full-year earnings is $1.36 per share. HC Wainwright also issued estimates for Corcept Therapeutics' Q3 2025 earnings at $0.32 EPS, Q4 2025 earnings at $0.70 EPS, FY2025 earnings at $1.29 EPS, FY2026 earnings at $3.56 EPS, FY2027 earnings at $7.33 EPS, FY2028 earnings at $10.47 EPS and FY2029 earnings at $12.96 EPS.

Corcept Therapeutics (NASDAQ:CORT - Get Free Report) last released its quarterly earnings data on Monday, May 5th. The biotechnology company reported $0.17 earnings per share for the quarter, hitting analysts' consensus estimates of $0.17. Corcept Therapeutics had a net margin of 22.35% and a return on equity of 24.54%. The business had revenue of $157.21 million for the quarter, compared to analysts' expectations of $177.93 million. During the same quarter last year, the company earned $0.25 EPS. The company's revenue for the quarter was up 7.1% compared to the same quarter last year.

A number of other brokerages have also issued reports on CORT. Piper Sandler boosted their price target on Corcept Therapeutics from $128.00 to $131.00 and gave the stock an "overweight" rating in a research report on Thursday, April 3rd. StockNews.com upgraded shares of Corcept Therapeutics from a "hold" rating to a "buy" rating in a research report on Tuesday, May 6th. Truist Financial set a $135.00 price target on shares of Corcept Therapeutics in a research report on Tuesday, May 6th. Finally, Canaccord Genuity Group increased their price objective on shares of Corcept Therapeutics from $130.00 to $142.00 and gave the company a "buy" rating in a report on Tuesday, April 1st. Six analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the stock has an average rating of "Buy" and an average price target of $138.25.

Corcept Therapeutics Stock Performance

Shares of NASDAQ CORT traded down $1.15 during midday trading on Thursday, hitting $70.23. 953,391 shares of the company's stock were exchanged, compared to its average volume of 1,123,426. Corcept Therapeutics has a twelve month low of $26.87 and a twelve month high of $117.33. The company has a debt-to-equity ratio of 0.01, a current ratio of 3.70 and a quick ratio of 3.64. The firm has a market cap of $7.45 billion, a P/E ratio of 55.74 and a beta of 0.22. The stock's 50 day moving average price is $66.86 and its 200-day moving average price is $60.97.

Institutional Investors Weigh In On Corcept Therapeutics

Large investors have recently made changes to their positions in the company. Wealthspire Advisors LLC acquired a new stake in Corcept Therapeutics during the 1st quarter valued at $458,000. Advyzon Investment Management LLC purchased a new position in shares of Corcept Therapeutics during the first quarter valued at $217,000. New Age Alpha Advisors LLC raised its position in Corcept Therapeutics by 35.7% during the first quarter. New Age Alpha Advisors LLC now owns 4,775 shares of the biotechnology company's stock valued at $545,000 after buying an additional 1,255 shares during the period. Bank of Nova Scotia acquired a new position in Corcept Therapeutics during the first quarter valued at $203,000. Finally, PNC Financial Services Group Inc. lifted its stake in Corcept Therapeutics by 24.4% in the 1st quarter. PNC Financial Services Group Inc. now owns 13,190 shares of the biotechnology company's stock worth $1,507,000 after acquiring an additional 2,584 shares in the last quarter. Institutional investors and hedge funds own 93.61% of the company's stock.

Insider Activity

In other Corcept Therapeutics news, insider Joseph Douglas Lyon sold 421 shares of the business's stock in a transaction dated Monday, March 24th. The stock was sold at an average price of $60.58, for a total transaction of $25,504.18. Following the sale, the insider now owns 9,009 shares in the company, valued at approximately $545,765.22. The trade was a 4.46 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, insider Sean Maduck sold 18,303 shares of the firm's stock in a transaction dated Monday, March 3rd. The stock was sold at an average price of $60.69, for a total transaction of $1,110,809.07. Following the completion of the transaction, the insider now owns 85,622 shares of the company's stock, valued at approximately $5,196,399.18. The trade was a 17.61 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last quarter, insiders sold 236,738 shares of company stock worth $20,476,238. Corporate insiders own 20.80% of the company's stock.

About Corcept Therapeutics

Corcept Therapeutics Incorporated engages in discovery and development of drugs for the treatment of severe endocrinologic, oncologic, metabolic, and neurologic disorders in the United States. It offers Korlym tablets medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous cushing's syndrome; and who have type 2 diabetes mellitus or glucose intolerance and have failed surgery or are not candidates for surgery.